HNSCC Clinical Trials

24 studies are recruiting for hnscc in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

   This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSD, La Jolla, California

   Locations

   54 in total

   Run by

   Genmab

   See if you can join NCT03526835 on ClinicalTrials.gov

2. A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

   This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of [225Ac]Ac-AKY-2519 in participants with B7-H3 imaging positive soli…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Biogenix Molecular, LLC, Miami, Florida

   Locations

   2 in total

   Run by

   Aktis Oncology, Inc.

   See if you can join NCT07887971 on ClinicalTrials.gov

3. TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma

   The goal of this clinical trial is to learn if an experimental, personalized cancer vaccine called TMV vaccine is safe and to find the best dose to study in future trials. The study includes adults with head and neck squamous cell carcinoma that has come back in or near the same area after earlier …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Run by

   Metaclipse Therapeutics Corporation

   See if you can join NCT07898124 on ClinicalTrials.gov

4. Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)

   The goal of this clinical trial is to learn whether intratumoral (injected directly into the tumor) fluorescently labeled nivolumab (nivo800) is safe for adults with head and neck squamous cell carcinoma (HNSCC) who are scheduled to undergo surgery. Researchers also want to learn how well nivo800 t…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Run by

   Vanderbilt-Ingram Cancer Center

   See if you can join NCT07741565 on ClinicalTrials.gov

5. Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

   The goal of this Phase 1 clinical trial is to evaluate the safety and feasibility of nivolumab-IRDye800CW (nivo800) as a molecular imaging agent in adults with biopsy-confirmed or presumed head and neck squamous cell carcinoma (HNSCC) who are scheduled to undergo standard-of-care surgical resection…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Run by

   Vanderbilt-Ingram Cancer Center

   See if you can join NCT07460765 on ClinicalTrials.gov

6. A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

   A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site 105 - START Los Angeles, Los Angeles, California

   Locations

   8 in total

   Run by

   EpiBiologics

   See if you can join NCT07462377 on ClinicalTrials.gov

7. A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

   A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   ALX Center 9, La Jolla, California

   Locations

   12 in total

   Run by

   ALX Oncology Inc.

   See if you can join NCT07085091 on ClinicalTrials.gov

8. A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

   A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors. The main goals of this study are to: * Find the recommended dose of TS-104 that can safely be given to p…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site 06, Maumee, Ohio

   Locations

   3 in total

   Run by

   TwoStep Therapeutics, Inc.

   See if you can join NCT07814248 on ClinicalTrials.gov

9. Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

   The goal of this clinical trial is to assess the safety and tolerability of a virus replicon particle (VRP) encapsulated saRNA encoding IL-12 when injected into in head and neck cancer patients. The main questions being addressed are: The safety and tolerability of intratumoral (IT) injections of V…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University, Stanford, California

   Run by

   VLP Therapeutics

   See if you can join NCT06736379 on ClinicalTrials.gov

10. First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

    The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale Cancer Center, New Haven, Connecticut

    Locations

    20 in total

    Run by

    Tubulis GmbH

    See if you can join NCT06657222 on ClinicalTrials.gov

11. ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

    Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the M…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Highlands Oncology Group, Rogers, Arkansas

    Locations

    14 in total

    Run by

    Adcendo ApS

    See if you can join NCT06597721 on ClinicalTrials.gov

12. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

    This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Normunity Investigational Site, Denver, Colorado

    Locations

    18 in total

    Run by

    Normunity AccelCo, Inc.

    See if you can join NCT07182149 on ClinicalTrials.gov

13. A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

    Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participan…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05859074 on ClinicalTrials.gov

14. Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

    This study is exploring the use of Panitumumab in Head and Neck Cancer. Panitumumab is an approved drug named Vectibix and is used as an anti-cancer agent in other cancers such as colorectal cancer. It works by attaching to the cancer cell in a unique way that allows the drug to get into the cancer…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Vanderbilt-Ingram Cancer Center

    See if you can join NCT06819228 on ClinicalTrials.gov

15. A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

    The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allo…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04722523 on ClinicalTrials.gov

16. Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

    Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for which current standard of care treatment for their stage of disease would…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    Dan Zandberg

    See if you can join NCT04114136 on ClinicalTrials.gov

17. A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

    The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combinat…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Precision NextGen Oncology and Research Center, Beverly Hills, California

    Locations

    10 in total

    Run by

    Epkin

    See if you can join NCT06789172 on ClinicalTrials.gov

18. High-Resolution PET-CT Imaging for Surgical Margin Visualization

    Imaging will be exploratory and be used intraoperatively. There have been no discovered risks associated with the device to be used in this study, and none are anticipated given the diagnostic and non-invasive, 'ex vivo' nature of device use. Of note, the surgical resection will proceed as per stan…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Vanderbilt-Ingram Cancer Center

    See if you can join NCT06915454 on ClinicalTrials.gov

19. A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

    This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    9 in total

    Run by

    ImmVira Pharma Co. Ltd

    See if you can join NCT04370587 on ClinicalTrials.gov

20. A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

    The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    10 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT06682793 on ClinicalTrials.gov

21. Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC

    This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck Squamous Cell Carcinoma. These are subjects who have undergone surgery or will be undergoing surgery.

    Stage

    Phase 2

    Ages

    18 to 79

    Site

    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT06693323 on ClinicalTrials.gov

22. Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

    The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HN…

    Stage

    Not phased

    Ages

    65 and older

    Site

    Jena University Hospital, Jena,

    Locations

    18 in total

    Run by

    University Hospital Freiburg

    See if you can join NCT05337631 on ClinicalTrials.gov

23. Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

    Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the un…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Irvine, Irvine, California

    Locations

    4 in total

    Run by

    CJ Bioscience, Inc.

    See if you can join NCT05877430 on ClinicalTrials.gov

24. A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

    Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Arizona, Phoenix, Arizona

    Locations

    4 in total

    Run by

    SparX Biotech(Jiangsu) Co., Ltd.

    See if you can join NCT06259552 on ClinicalTrials.gov